Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.

PloS one - 1 Jan 2015

Joshi Monika, Rice Shawn J, Liu Xin, Miller Bruce, Belani Chandra P

Abstract excerpt

V-Raf Murine Sarcoma Viral Oncogene Homolog B (BRAF) mutated lung cancer is relatively aggressive and is resistant to currently available therapies. In a recent phase II study for patients with BRAF-V600E non-small cell lung cancer (NSCLC), BRAF V600E inhibitor demonstrated evidence of activity, but 30% of this selected group progressed while on treatment, suggesting a need for developing alternative strategies....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Erlotinib Hydrochloride
Share to G1 Phase
Share to Indoles

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Pyridones

Share to Pyrimidinones

Share to Quinazolines

Share to Sulfonamides

Share to Vemurafenib

Source

Open in PubMed Open full text

Identifiers

PMID: 25706985
DOI: 10.1371/journal.pone.0118210
PMCID: PMC4338247

Genes

BRAF

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.PMID 25706985Read ↗

Targeting BRAF-mutant non-small cell lung cancer: Current status and future directions.Semantic proximity Read ↗

Ongoing progress in BRAF-mutated non-small cell lung cancer.Semantic proximity Read ↗

BRAF mutant non-small cell lung cancer and treatment with BRAF inhibitors.Semantic proximity Read ↗

Dabrafenib in combination with trametinib in the treatment of patients with BRAF V600-positive advanced or metastatic non-small cell lung cancer: clinical evidence and experience.Semantic proximity Read ↗

BRAF Alterations as Therapeutic Targets in Non-Small-Cell Lung Cancer.Semantic proximity Read ↗

Vemurafenib/dabrafenib and trametinibSemantic proximity Read ↗

Pan-RAF and MEK vertical inhibition enhances therapeutic response in non-V600 BRAF mutant cells.Semantic proximity Read ↗

Type II RAF inhibitor causes superior ERK pathway suppression compared to type I RAF inhibitor in cells expressing different BRAF mutant types recurrently found in lung cancerSemantic proximity Read ↗

Dabrafenib and trametinib for the treatment of non-small cell lung cancer.Semantic proximity Read ↗

Targeting MEK in non-small cell lung cancer.Semantic proximity Read ↗

Trametinib in the treatment of multiple malignancies harboring MEK1 mutations.Semantic proximity Read ↗

Erlotinib and Trametinib in Patients With EGFR-Mutant Lung Adenocarcinoma and Acquired Resistance to a Prior Tyrosine Kinase Inhibitor.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.